The Click Activated Protodrugs Against Cancer (CAPAC) platform enables the activation of
powerful cancer drugs at tumors. CAPAC utilizes a click chemistry reaction between …

In this work, a tumor growth intervention by localized drug synthesis within the tumor volume,
using the enzymatic repertoire of the tumor itself, is presented. Towards the overall success …

Antibody-drug conjugates (ADC) are spearheading vectorized chemotherapy against
cancer, with 4 FDA-approved ADCs and 79 in clinical trials. However, most ADCs are …

Naturally occurring antimitotic pentapeptide dolastatin 10 (1, Figure 1)[1] and its synthetic
analogue auristatin E (AE, 2)[2] possess subnanomolar cytotoxicity against many human …

A key challenge in anticancer therapy is to gain control over the biodistribution of cytotoxic
drugs. The most promising strategy consists in conjugating drugs to tumor-targeting carriers …

Auristatins are highly potent antimitotic agents that have received considerable attention
because of their activities when targeted to tumor cells in the form of antibody− drug …

Auristatins are a class of highly cytotoxic tubulin-disrupting peptides, which have shown
limited therapeutic effect as free agents in clinical trials. In our continuing effort to develop …

Auristatins are important payloads used in antibody drug conjugates (ADCs), and the most
well-known compound family member, monomethyl auristatin (MMAE), is used in two Food …

Background and Purpose Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …

Auristatins, a class of clinically validated anti-tubulin agents utilized as payloads in antibody–
drug conjugates, are generally classified by their membrane permeability and the extent of …